Sarepta Could More Than Double Its Addressable Market In A Few Years, But Eteplirsen Isn't The 'Be All End All'

By: via Benzinga
Sarepta Therapeutics Inc (NASDAQ: SRPT) announced the commencement of dosing in the Phase III ESSENCE study of SRP-4045 and ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.